HomeHealth

Health

Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ACCORD Phase 3 Trial in Alzheimer’s Disease Agitation

Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ACCORD Phase 3 Trial in Alzheimer’s Disease Agitation

November 28, 2022

C4X Discovery Holdings plc: C4XD signs exclusive global licence worth up to $402 million¹ with AstraZeneca for the development and commercialisation of NRF2 Activator programme

C4X Discovery Holdings plc: C4XD signs exclusive global licence worth up to $402 million¹ with AstraZeneca for the development and commercialisation of NRF2 Activator programme

November 28, 2022

Hoth Therapeutics Announces Its New Product, Ht-Alz Therapeutic, Gives Cognitive Improvements In Alzheimer’s Disease Model In Mouse

Hoth Therapeutics Announces Its New Product, Ht-Alz Therapeutic, Gives Cognitive Improvements In Alzheimer’s Disease Model In Mouse

July 26, 2022

Bristol-Myers (BMY) to Post Q2 Earnings: What is in the Cards?

Bristol-Myers (BMY) to Post Q2 Earnings: What is in the Cards?

July 25, 2022

Is a Beat in Store for Alkermes (ALKS) This Earnings Season?

Is a Beat in Store for Alkermes (ALKS) This Earnings Season?

July 25, 2022

Centene (CNC) Gears Up for Q2 Earnings: What Lies Ahead?

Centene (CNC) Gears Up for Q2 Earnings: What Lies Ahead?

July 25, 2022

Exact Sciences (EXAS) to Post Q2 Earnings: What’s in Store?

Exact Sciences (EXAS) to Post Q2 Earnings: What’s in Store?

July 25, 2022

Gilead (GILD) Gets Positive CHMP Opinion for Veklury & Tecartus

Gilead (GILD) Gets Positive CHMP Opinion for Veklury & Tecartus

July 25, 2022

Biogen Inc. (BIIB) Upgraded to Buy: What Does It Mean for the Stock?

Biogen Inc. (BIIB) Upgraded to Buy: What Does It Mean for the Stock?

July 25, 2022

GSK Gears Up to Report Q2 Earnings: What’s in the Cards?

GSK Gears Up to Report Q2 Earnings: What’s in the Cards?

July 25, 2022

« 1 … 33 34 35 36 37 … 942 »